Researchers have identified a protein that powers the virulence of the bacteria that causes gonorrhea, opening the possibility of a new target for antibiotics and, even better, a vaccine.
The findings, published today in PLOS Pathogens, are especially important since the microbe, Neisseria gonorrhoeae, is considered a “superbug” because of its resistance to all classes of antibiotics available for treating infections.
Gonorrhea, a sexually transmitted disease that results in 78 million new cases worldwide each year, is highly damaging if untreated or improperly treated.
It can lead to endometritis, pelvic inflammatory disease, ectopic pregnancy, epididymitis and infertility. Babies born to infected mothers are at increased risk of blindness.
“The infections very often are silent,” said Oregon State University researcher Aleksandra Sikora. “Up to 50 percent of infected women don’t have symptoms, but those asymptomatic cases can still lead to some very severe consequences for the patient’s reproductive health, miscarriage or premature delivery.”
The need for better antibiotic therapy, and a vaccine, is pressing. N. gonorrhoeae strains resistant to the last effective treatment options have emerged, and failures in treatment are occurring.
Sikora and her research team at the OSU/OHSU College of Pharmacy and Ann Jerse’s lab at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, collaborated to discover a novel lipoprotein that N. gonorrhoeae uses to defeat the body’s first line of innate immune defense.
The body relies on enzymes known as lysozymes that, as their name suggests, thwart bacteria by causing their cell wall to lyse, or break apart. Lysozymes are abundant both in epithelial cells, which make up the tissue on the outside of organs and the inside of body cavities, and in the phagocytic cells that protect the body by ingesting foreign particles and bacteria.
In turn, many gram-negative bacteria – characterized by their cell envelope that includes a protective outer membrane – have developed ways of defeating lysozymes. Prior to the work by Sikora’s team, however, only one lysozyme-fighting protein had been discovered in the Neisseria genus.
Now that new targets have been identified, they can be explored as bullseye candidates for new antibiotics or a vaccine – if the lysozyme inhibitor can itself be inhibited, then the bacteria’s infection-causing ability is greatly reduced.
Sikora and her collaborators named the new protein SliC, short for surface-exposed lysozyme inhibitor of c-type lysozyme.
Studying SliC’s function in culture as well as in a gonorrhea mouse model – mice were infected with N. gonorrhoeae, then checked for SliC expression at one, three and five days – researchers determined the protein was essential to bacterial colonization because of its anti-lysozyme role.
“This is the first time an animal model has been used to demonstrate a lysozyme inhibitor’s role in gonorrhea infection,” Sikora said. “Together, all of our experiments show how important the lysozyme inhibitor is. This is very exciting.”
The Latest on: Gonorrhea
[google_news title=”” keyword=”gonorrhea” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gonorrhea
- These 50 cities have the highest STI rates in the USon May 6, 2024 at 4:00 pm
The worst place for STIs, perhaps surprisingly is Philadelphia. One in 65 residents were diagnosed with an infection in 2022 in the city of brotherly love. This was followed by Memphis (TN), Jackson ...
- Emergence of Multidrug-resistant, Extensively Drug-resistant and Untreatable Gonorrheaon May 5, 2024 at 5:00 pm
An era of untreatable gonorrhea may be approaching, which represents an exceedingly serious public health problem. Herein, we review the evolution, origin and spread of antimicrobial resistance ...
- First-in-Class Antibiotic Effective Against Urogenital Gonorrheaon April 29, 2024 at 5:00 pm
Opens in a new tab or window Gepotidacin, an investigational antibiotic, proved noninferior to dual therapy for the treatment of uncomplicated urogenital gonorrhea, according to results of the ...
- Blue Earth County sees slight dip in STI cases,on April 26, 2024 at 3:14 pm
MANKATO — Blue Earth County saw a slight dip in chlamydia and gonorrhea cases in 2023 from 2022, the Minnesota Department of Health reported this week.
- Study: High percentage of chlamydia and gonorrhea patients not receiving CDC recommended treatmenton April 25, 2024 at 10:39 pm
Chlamydia and gonorrhea are the two most common sexually transmitted infections (STIs) in the United States, impacting 2.4 million in 2021, and the number is rising.
- Study reports chlamydia and gonorrhea more likely to be treated per CDC guidelines in certain populationson April 25, 2024 at 1:38 pm
Chlamydia and gonorrhea are the two most common sexually transmitted infections (STIs) in the United States, impacting 2.4 million in 2021, and the number is rising.
- Can Gonorrhea Make You Infertile?on April 21, 2024 at 5:00 pm
Yes, gonorrhea can lead to infertility and other health effects if left untreated. Antibiotic treatment can cure gonorrhea and reduce your chance of long-term complications. When the fallopian ...
- Meningococcal vaccine found to be cost-effective at protecting men against gonorrheaon April 16, 2024 at 5:01 pm
Protecting men who have sex with men against gonorrhea with the 4CMenB meningococcal B vaccine is cost-effective; Imperial College London study finds Gonorrhea is a sexually transmitted disease ...
- Emergence of Multidrug-resistant, Extensively Drug-resistant and Untreatable Gonorrheaon April 14, 2024 at 5:00 pm
No writing assistance was utilized in the production of this manuscript. Gonorrhea burden and multidrug-resistance in N. gonorrhoeae remain major public health concerns that are poorly surveyed ...
via Bing News